Chemours shares slump as top executives put on leave, results delayed again
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- White House blocks CNN from Air Force One trip, Washington Post reports
BMO Capital Downgrades Chemours (CC) to Underperform
February 29, 2024 7:59 AM ESTBMO Capital analyst John McNulty downgraded Chemours (NYSE: CC) from Market Perform to Underperform with a price target of $19.00 (from $45.00)
The analyst comments "Following a two-week delay in their reporting, Chemours has announced a further delay in filing their results and... More
